论文部分内容阅读
文章介绍了新的药物涂层球囊技术(DCBs)预防介入术后血管再狭窄的作用机制是通过在球囊表面被以抗组织增生药物。由于扩压作用迅速转移,释放药物到血管壁中与细胞微管蛋白结合,导致微管功能障碍而产生抗组织增生、减轻炎症作用的,目前在冠状动脉介入、外周血管介入中初步应用效果明显。文章还述评了今后重点需要研究DCBs的优化、球囊涂层载体技术、球囊技术与其他技术如斑块切除术或支架技术的结合研究、DCBs仅需要一次治疗还是多次使用更佳、血管壁对涂层药物吸附攮取的研究、涂层药物有无毒副反应及毒理如何等,以便促进其广泛临床应用。
The article describes the mechanism by which new drug-coated balloon techniques (DCBs) prevent vascular restenosis following interventional therapy by administering anti-tissue proliferative drugs to the surface of the balloon. As the rapid diffusion of the role of the transfer, the release of drugs to the vascular wall and tubulin binding, resulting in microtubule dysfunction and have anti-tissue proliferation, reduce inflammation, the current coronary intervention, peripheral vascular intervention initially effective . The article also reviews the future focus on the need to study the optimization of DCBs, balloon coating carrier technology, balloon technology and other technologies such as plaque resection or stent technology combined study, DCBs only need a single treatment or multiple use better, blood vessels The study of the adsorption of the drug on the wall, the nontoxic side effects of the coated drug and the toxicology, in order to promote its widespread clinical application.